COMPARATIVE STUDY BETWEEN BELOTECAN/CISPLATIN AND ETOPOSIDE/CISPLATIN (COMBAT) IN PATIENTS WITH PREVIOUSLY UNTREATED, EXTENSIVE STAGE SMALL CELL LUNG CANCER

被引：0
|
作者：
Oh, In-Jae [1 ]
Kim, Kyu-Sik [1 ]
Kim, Young-Chul [1 ]
Na, Kook-Joo [1 ]
Ahn, Sung-Ja [1 ]
Song, Sang-Yun [1 ]
Choi, Yoo-Duk [1 ]
Yoon, Seong-Hoon [1 ]
Lee, Boram [1 ]
Yu, Jinyeong [1 ]
机构：
[1] Chonnam Natl Univ, Hwasun Hosp, Lung Canc Clin, Kwangju, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
belotecan; small cell lung cancer; topoisomerase I inhibitor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.10-031
引用
收藏
页码：S1171 / S1171
页数：1
相关论文
共 50 条
  • [21] A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
    Zatloukal, P.
    Cardenal, F.
    Szczesna, A.
    Gorbunova, V.
    Moiseyenko, V.
    Zhang, X.
    Cisar, L.
    Soria, J. -C.
    Domine, M.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2010, 21 (09) : 1810 - 1816
  • [22] Phase II Study of Celecoxib with Cisplatin Plus Etoposide in Extensive-Stage Small Cell Lung Cancer
    Araujo, Antonio M. F.
    Mendez, Jose C.
    Coelho, Ana L.
    Sousa, Berta
    Barata, Fernando
    Figueiredo, Ana
    Amaro, Teresina
    Azevedo, Isabel
    Soares, Marta
    CANCER INVESTIGATION, 2009, 27 (04) : 391 - 396
  • [23] Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer
    Zheng-tao Zhou
    Fu-xiang Zhou
    Qing Wei
    Li-yong Zou
    Bin-fang Qin
    Xu-shen Peng
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1027 - 1032
  • [24] Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer
    Araujo, Antonio M. F.
    Mendez, Jose C.
    Sousa, Berta
    Barata, Fernando
    Figueiredo, Ana
    Amaro, Teresina
    Coelho, Ana
    Azevedo, Isabel
    Soares, Marta
    ANNALS OF ONCOLOGY, 2006, 17 : 232 - 232
  • [25] Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer
    Hong, Y. S.
    Lee, H. R.
    Park, S.
    Lee, S. C.
    Hwang, I. G.
    Park, B-B
    Lee, J.
    Ahn, J. S.
    Ahn, M-J
    Lim, H. Y.
    Park, K.
    BRITISH JOURNAL OF CANCER, 2006, 95 (12) : 1648 - 1652
  • [26] A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer
    Berghmans, Thierry
    Scherpereel, Arnaud
    Meert, Anne-Pascale
    Giner, Vicente
    Lecomte, Jacques
    Lafitte, Jean-Jacques
    Leclercq, Nathalie
    Paesmans, Marianne
    Sculier, Jean-Paul
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [27] Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer
    Y S Hong
    H R Lee
    S Park
    S C Lee
    I G Hwang
    B-B Park
    J Lee
    J S Ahn
    M-J Ahn
    H Y Lim
    K Park
    British Journal of Cancer, 2006, 95 : 1648 - 1652
  • [28] A comparative study on etoposide combined with lobaplatin or cisplatin in the first-line treatment of extensive-stage small cell lung cancer
    Li, Shujun
    Liang, Yahai
    Wu, Yanxia
    Huang, Zhong
    Lin, Yanming
    Yang, Zhixiong
    Chen, Hualin
    Wu, Aibing
    JOURNAL OF BUON, 2020, 25 (03): : 1490 - 1496
  • [29] Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer
    Lara, Primo N., Jr.
    Gandara, David R.
    Natale, Ronald B.
    CLINICAL LUNG CANCER, 2006, 7 (05) : 353 - 356
  • [30] S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC)
    Natale, R. B.
    Lara, P. N.
    Chansky, K.
    Crowley, J. J.
    Jett, J. R.
    Carleton, J. E.
    Kuebler, J. P.
    Lenz, H. J.
    Mack, P. C.
    Gandara, D. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345